Skip to main content
. 2010 Aug;12(8):700–708. doi: 10.1111/j.1463-1326.2010.01222.x

Figure 2.

Figure 2

Panel (A): changes in mean (±s.e.) HbA1c during the 12-week treatment with vildagliptin 50 mg bid (open triangles) or voglibose 0.2 mg tid (closed circles). Panel (B): least square mean (±s.e.) change in HbA1c at endpoint under treatment with vildagliptin 50 mg bid (white bar) or voglibose 0.2 mg tid (black bar). *p < 0.001 vs voglibose. HbA1c, haemoglobin A1c.